Welcome to our dedicated page for Sera Prognostics SEC filings (Ticker: SERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Sera Prognostics, Inc. (NASDAQ: SERA), a Salt Lake City–based health diagnostics company focused on precision pregnancy care and preterm birth risk prediction. As a public company, Sera files annual, quarterly, and current reports that describe its financial condition, operations, and key clinical and commercial developments.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed discussions of Sera’s business, including its focus on the PreTRM® Test, a blood-based biomarker test for individualized risk prediction of spontaneous preterm birth in asymptomatic singleton pregnancies. These filings typically include information on revenues, operating expenses, research and development activities, and risk factors relevant to the company’s diagnostics business.
Current reports on Form 8-K document material events such as the release of quarterly financial results and significant clinical milestones. Recent 8-K filings reference press releases announcing second and third quarter financial results and the acceptance of the PRIME study for publication in a peer-reviewed journal. These filings help readers track how clinical evidence, such as the PRIME randomized controlled trial, connects to Sera’s commercial and strategic plans.
Users can also monitor Form 4 and other insider transaction filings, when available, to see reported trades by directors, officers, or significant shareholders. Stock Titan’s tools surface new SERA filings as they appear in the SEC’s EDGAR system and provide AI-powered summaries to explain key points, highlight important sections in lengthy documents, and make it easier to understand how disclosures about the PreTRM Test, payer engagement, and financial performance may relate to the company’s overall trajectory.
SERA submitted a Form 144 notice to sell Class A Common shares tied to Restricted Stock Unit vesting. The filing lists Class A Common securities with a proposed sale date of 03/11/2026 and shows an entry of 1,517 and another figure 3,097 adjacent to the security line. The filing also reports securities sold during the past three months by John J. Boniface: 1,332 shares on 12/10/2025 and 3,038 shares on 03/09/2026.
SERA filed a Form 144 disclosing intended sales of Class A Common stock tied to recent RSU vesting and open-market dispositions. The filing lists a Restricted Stock Unit vesting of 6,069 Class A shares on 03/10/2026 and shows sales by Austin Aerts of 873 shares on 12/10/2025, 674 shares on 03/09/2026, and 6,069 shares on 03/10/2026. The cover lists 38,594,793 shares with a date of 03/11/2026 and trading venue NASDAQ (contextual baseline).
SERA submitted a Form 144 notifying a proposed sale of Class A Common shares in connection with restricted stock unit vesting. The filing references a vesting date of 03/10/2026 and lists prior sales of 4,155 shares on 12/10/2025.
SERA reported a Form 144 disclosing proposed sales of Class A Common stock tied to RSU vesting and recent small dispositions by a reporting person. The filing lists a planned sale dated 03/10/2026 for shares associated with Restricted Stock Unit Vesting and shows prior sales of 873 shares on 12/10/2025 and 674 shares on 03/09/2026 by Austin Aerts.
Sera Prognostics Chief Data Officer Paul Kearney reported an open-market sale of 2,026 shares of Class A common stock at a weighted average price of $1.96 per share on March 9, 2026. According to the disclosure, these shares were sold solely to cover tax withholding obligations arising from the vesting of restricted stock units under a mandatory “sell to cover” arrangement, meaning the transaction was not discretionary. Following this tax-related sale, Kearney continues to hold 165,357 shares of Sera Prognostics common stock.
Sera Prognostics General Counsel Benjamin Jackson reported a sale of 3,119 shares of Class A Common Stock at a weighted average price of $1.96 per share. This reduced his direct holdings to 115,747 shares. The shares were sold to cover tax withholding obligations from vesting restricted stock units under a mandatory “sell to cover” arrangement, meaning the transaction was not discretionary. The block trade was executed at prices ranging from $1.87 to $2.03 per share.
SERA PROGNOSTICS, INC. Chief Information Officer Robert Gardner reported a mandated sale of 3,360 shares of Class A common stock at a weighted average price of $1.96 per share. The shares were sold solely to cover tax withholding obligations tied to vesting restricted stock units under a required “sell to cover” election, rather than as a discretionary trade. Following the transaction, he directly holds 77,428 shares.
Sera Prognostics Chief Scientific Officer John J. Boniface reported a mandated share sale to cover taxes on vesting RSUs. He sold 3,038 shares of Class A Common Stock at a weighted average price of $1.96 per share, in block trades between $1.87 and $2.03. The company required a “sell to cover” transaction for tax withholding, so this was not a discretionary trade. After the sale, he directly owned 147,359 shares.
SERA PROGNOSTICS, INC. Chief Financial Officer Austin Aerts reported a small, mandated sale of Class A common stock to cover taxes from vesting restricted stock units. He sold 674 shares in a block trade at a weighted average price of $1.96 per share, with individual trades ranging from $1.87 to $2.03. After this tax-related sell-to-cover transaction, Aerts directly holds 271,540 shares of the company’s stock, indicating the sale was minor relative to his overall position and not a discretionary open-market sale.
SERA submitted a Form 144 disclosing a proposed sale of Class A Common stock. The filing identifies the transaction type as Restricted Stock Unit Vesting and lists an effective date of 03/09/2026. The filing also records a prior sale by Paul Kearney on 12/10/2025.